Faculty Profiles - BABA Hiroshsi

Papers - BABA Hiroshsi

Division display 1 - 20 of about 225 ／ All the affair displays >>

Visualization of primary afferent-evoked excitation of spinal dorsal horn neurons using an intracellular Ca2+ imaging technique in adult rat spinal cord slices Reviewed

Hiroshi Baba, Nobuko Ohashi

Journal of Anesthesia 39 ( 2 ) 231 - 247 2025.4

Authorship：Lead author,　Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：Springer Science and Business Media LLC

File： Baba (JA, 2025)on line.pdf

DOI： 10.1007/s00540-024-03451-0

researchmap

Other Link： https://link.springer.com/article/10.1007/s00540-024-03451-0/fulltext.html

動画5 Reviewed

2025.4

Visualization of primary afferent-evoked excitation of spinal dorsal horn neurons using an intracellular Ca2+ imaging technique in adult rat spinal cord slices

2025.4

動画2

画

2025.4

動画3

2025.4

動画4

2025.4

Ivabradine reduces neuropathic pain after spinal cord injury by inhibiting excitatory synaptic transmission in the spinal dorsal horn Reviewed

Nobuko Ohashi, Masayuki Ohashi, Rintaro Hoshino, Hiroyuki Deguchi, Hiroshi Baba

Neuroscience Letters 848 138113 - 138113 2025.1

Effect of Remimazolam on Transcranial Electrical Motor-evoked Potential in Spine Surgery: A Prospective, Preliminary, Dose-escalation Study

Shuichiro Kurita, Kenta Furutani, Yusuke Mitsuma, Hiroyuki Deguchi, Tomoaki Kamoda, Yoshinori Kamiya, Hiroshi Baba

Journal of Neurosurgical Anesthesiology 22 2024.7

Authorship：Last author Publishing type：Research paper (scientific journal) Publisher：Ovid Technologies (Wolters Kluwer Health)

Background:

Some anesthetic drugs reduce the amplitude of transcranial electrical motor-evoked potentials (MEPs). Remimazolam, a new benzodiazepine, has been suggested to have little effect on MEP amplitude. This prospective, preliminary, dose-escalation study aimed to assess whether remimazolam is associated with lower MEP amplitude in a dose-dependent manner.

Methods:

Ten adult patients scheduled for posterior spinal fusion were included in this study. General anesthesia was induced with a continuous infusion of remifentanil and remimazolam. After the patient lost consciousness, the infusion rate of remimazolam was set to 1 mg/kg/h, and the patient underwent tracheal intubation. Baseline MEPs were recorded under 1 mg/kg/h of remimazolam in a prone position. Thereafter, the infusion rate of remimazolam was increased to 2 mg/kg/h, with a bolus of 0.1 mg/kg. Ten minutes after the increment, the evoked potentials were then recorded again. The primary endpoint was the MEP amplitude recorded in the left gastrocnemius muscle at 2 time points.

Results:

There was no difference in MEP amplitude recorded from the left gastrocnemius muscle before and after increasing remimazolam (median [interquartile range]: 0.93 [0.65 to 1.25] mV and 0.70 [0.43 to 1.26] mV, respectively;P=0.08). The average time from the cessation of remimazolam administration to neurological examination after surgery was 4 minutes using flumazenil.

Conclusions:

This preliminary study suggests that increasing remimazolam from 1 to 2 mg/kg/h might have an insignificant effect on transcranial electric MEPs.

File： Kurita(2024).png

DOI： 10.1097/ana.0000000000000983

PubMed

researchmap

Actions of remimazolam on inhibitory transmission of rat spinal dorsal horn neurons Reviewed

Rintaro Hoshino, Nobuko Ohashi, Daisuke Uta, Masayuki Ohashi, Hiroyuki Deguchi, Hiroshi Baba

Journal of Pharmacological Sciences 155 ( 2 ) 63 - 73 2024.6

Analgesic effects of oral Yokukansan on acute postoperative pain and involvement of the serotonin nervous system: a mouse model study Reviewed

Shuichiro Kurita, Mika Sasaki, Moegi Tanaka, Yoshinori Kuwabara, Yukino Ogasawara, Hiroshi Baba, Yoshinori Kamiya

BMC Complementary Medicine and Therapies 24 ( 1 ) 2024.5

Language：English Publishing type：Research paper (scientific journal) Publisher：Springer Science and Business Media LLC

Abstract

Background

Yokukansan, a traditional Japanese medicine (Kampo), has been widely used to treat neurosis, dementia, and chronic pain. Previous in vitro studies have suggested that Yokukansan acts as a partial agonist of the 5-HT1A receptor, resulting in amelioration of chronic pain through inhibition of nociceptive neuronal activity. However, its effectiveness for treating postoperative pain remains unknown, although its analgesic mechanism of action has been suggested to involve serotonin and glutamatergic neurotransmission. This study aimed to investigate the effect of Yokukansan on postoperative pain in an animal model.

Methods

A mouse model of postoperative pain was created by plantar incision, and Yokukansan was administered orally the day after paw incision. Pain thresholds for mechanical and heat stimuli were examined in a behavioral experiment. In addition, to clarify the involvement of the serotonergic nervous system, we examined the analgesic effects of Yokukansan in mice that were serotonin-depleted by para-chlorophenylalanine (PCPA) treatment and intrathecal administration of NAN-190, 5-HT1A receptor antagonist.

Results

Orally administered Yokukansan increased the pain threshold dose-dependent in postoperative pain model mice. Pretreatment of para-chlorophenylalanine dramatically suppressed serotonin immunoreactivity in the spinal dorsal horn without changing the pain threshold after the paw incision. The analgesic effect of Yokukansan tended to be attenuated by para-chlorophenylalanine pretreatment and significantly attenuated by intrathecal administration of 2.5 µg of NAN-190 compared to that in postoperative pain model mice without para-chlorophenylalanine treatment and NAN-190 administration.

Conclusion

This study demonstrated that oral administration of Yokukansan has acute analgesic effects in postoperative pain model mice. Behavioral experiments using serotonin-depleted mice and mice intrathecally administered with a 5-HT1A receptor antagonist suggested that Yokukansan acts as an agonist at the 5-HT1A receptor, one of the serotonin receptors, to produce analgesia.

File： Kurita(BMC,2024).pdf

DOI： 10.1186/s12906-024-04501-6

researchmap

Other Link： https://link.springer.com/article/10.1186/s12906-024-04501-6/fulltext.html

Influence of the descending pain-inhibiting serotonergic pathway on the antihyperalgesic effect of gabapentin in neuropathic pain model rats Reviewed

Harue Yanagimura, Mika Sasaki, Hiroshi Baba, Yoshinori Kamiya

Neuroscience Research 202 20 - 29 2024.5

Omega-conotoxin MVIIA reduces neuropathic pain after spinal cord injury by inhibiting N-type voltage-dependent calcium channels on spinal dorsal horn Reviewed

Nobuko Ohashi, Daisuke Uta, Masayuki Ohashi, Rintaro Hoshino, Hiroshi Baba

Frontiers in Neuroscience 18 2024.2

Authorship：Last author Language：English Publishing type：Research paper (scientific journal) Publisher：Frontiers Media SA

Spinal cord injury (SCI) leads to the development of neuropathic pain. Although a multitude of pathological processes contribute to SCI-induced pain, excessive intracellular calcium accumulation and voltage-gated calcium-channel upregulation play critical roles in SCI-induced pain. However, the role of calcium-channel blockers in SCI-induced pain is unknown. Omega-conotoxin MVIIA (MVIIA) is a calcium-channel blocker that selectively inhibits N-type voltage-dependent calcium channels and demonstrates neuroprotective effects. Therefore, we investigated spinal analgesic actions and cellular mechanisms underlying the analgesic effects of MVIIA in SCI. We used SCI-induced pain model rats and conducted behavioral tests, immunohistochemical analyses, and electrophysiological experiments (in vitro whole-cell patch-clamp recording and in vivo extracellular recording). A behavior study suggested intrathecal MVIIA administration in the acute phase after SCI induced analgesia for mechanical allodynia. Immunohistochemical experiments and in vivo extracellular recordings suggested that MVIIA induces analgesia in SCI-induced pain by directly inhibiting neuronal activity in the superficial spinal dorsal horn. In vitro whole-cell patch-clamp recording showed that MVIIA inhibits presynaptic N-type voltage-dependent calcium channels expressed on primary afferent Aδ-and C-fiber terminals and suppresses the presynaptic glutamate release from substantia gelatinosa in the spinal dorsal horn. In conclusion, MVIIA administration in the acute phase after SCI may induce analgesia in SCI-induced pain by inhibiting N-type voltage-dependent calcium channels on Aδ-and C-fiber terminals in the spinal dorsal horn, resulting in decreased neuronal excitability enhanced by SCI-induced pain.

File： Ohashi(Frontiers,2024).pdf

DOI： 10.3389/fnins.2024.1366829

researchmap

心臓血管手術時の予防投与薬剤：ステロイド, 抗菌薬 Reviewed

安部達也, 渡部達範, 馬場洋

臨床麻酔 47 ( 11 ) 1255 - 1261 2023.11

Structural and functional properties of spinal dorsal horn neurons after peripheral nerve injury change overtime via astrocyte activation Reviewed

Miyuki Kurabe, Mika Sasaki, Kenta Furutani, Hidemasa Furue, Yoshinori Kamiya, Hiroshi Baba

iScience 25 ( 12 ) 105555 - 105555 2022.12

褐色細胞腫患者の麻酔導入時にデキサメタゾン投与によると思われる高血圧発作をきたした1例

栗田秀一郎, 紙谷義孝, 馬場洋

日本集中治療医学会雑誌 29 ( Suppl.1 ) 671 - 671 2022.11

Neuronal Nitric Oxide Synthase Suppression Confers the Prolonged Analgesic Effect of Sciatic Nerve Block With Perineural Dexamethasone in Postoperative Pain Model Mice Reviewed

Keiichiro Matsuda, Mika Sasaki, Hiroshi Baba, Yoshinori Kamiya

The Journal of Pain 23 ( 10 ) 1765 - 1778 2022.10

Low-dose Droperidol Reduces the Amplitude of Transcranial Electrical Motor-evoked Potential: A Randomized, Double-blind, Placebo-controlled Trial. Reviewed International journal

Yusuke Mitsuma, Kenta Furutani, Hiroyuki Deguchi, Yoshinori Kamiya, Takahiro Tanaka, Nobutaka Kitamura, Hiroshi Baba

Journal of neurosurgical anesthesiology 34 ( 4 ) 424 - 428 2022.8

Authorship：Last author Language：English Publishing type：Research paper (scientific journal) Publisher：Ovid Technologies (Wolters Kluwer Health)

BACKGROUND: Low-dose droperidol has been reported to suppress the amplitude of transcranial electrical motor-evoked potentials (TCE-MEPs), but no randomized controlled trials have been conducted to assess this. This randomized, double-blinded, placebo-controlled trial aimed to test the hypothesis that low-dose droperidol reduced TCE-MEP amplitudes. METHODS: Twenty female patients with adolescent idiopathic scoliosis, aged between 12 and 20 years, and scheduled to undergo corrective surgery were randomly allocated to receive droperidol (20 µg/kg) or 0.9% saline. After recording baseline TCE-MEPs, the test drug was administered, following which TCE-MEP recordings were carried out every 2 minutes for up to 10 minutes. The primary outcome was the minimum relative TCE-MEP amplitude (peak-to-peak amplitude, percentage of baseline value) recorded in the left tibialis anterior muscle. Secondary outcomes included minimum relative MEP amplitudes recorded from all other muscle groups monitored in the study. Data are expressed as medians (interquartile range). RESULTS: The TCE-MEP amplitude of the left tibialis anterior muscle was significantly reduced following droperidol administration compared with saline (37% [30% to 55%] vs. 76% [58% to 93%], respectively, P<0.01). In the other muscles, the amplitudes were reduced in the droperidol group, except for the bilateral abductor pollicis brevis and the left quadriceps femoris muscles. The relative amplitude of the bilateral F waves recorded from the gastrocnemius was decreased in the droperidol group. CONCLUSIONS: Low-dose droperidol (20 µg/kg) reduced TCE-MEP amplitudes. Anesthesiologists should pay attention to the timing of droperidol administration during intraoperative TCE-MEP recordings, even if used in a low dose.

File： Mitsuma(J Neurosurg Anesth,2021).pdf

DOI： 10.1097/ANA.0000000000000784

PubMed

researchmap

Analgesic effect of ivabradine against inflammatory pain mediated by hyperpolarization-activated cyclic nucleotide–gated cation channels expressed on primary afferent terminals in the spinal dorsal horn Reviewed

Nobuko Ohashi, Daisuke Uta, Masayuki Ohashi, Hiroshi Baba

Pain 163 ( 7 ) 1356 - 1369 2022.7